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that function by inhibiting the synthesis of β-1,3-glucan in the cell wall and thus lead to 
lysis of the cell. In this work the effect of caspofungin on the release of peptides from 
non-growing cells of the yeast Candida albicans that had been exposed to the drug was 
monitored. Exposure to 0.19 μg/ml caspofungin resulted in the release of amino acids 
from cells and of both small and large molecular weight proteins as demonstrated by 
1- and 2-dimensional gel electrophoresis. Matrix-assisted laser desorption/ionization-
time of fl ight-mass spectrometry (MALDI-ToF) mass spectrometry was employed to 
identify a number of escaped peptides that were found to have increased in intensity 
upon exposure to the drug. A number of wall-associated proteins (e.g., phosphoglyc-
erate kinase) and a number of glycolytic enzymes (phosphoglycerate mutase 1, fruc-
tose-bisphosphate aldolase) were identifi ed. Importantly, several released proteins (e.g., 
pyruvate kinase, enolase 1, phosphoglycerate mutase, glyceraldehydes 3-phosphate 
dehydrogenase, fructose bisphosphate aldolase and alcohol dehydrogenase 1) are highly 
immunogenic in nature.  The results presented here demonstrate that non-growing C. 
albicans cells are susceptible to the effect of caspofungin and that the caspofungin-
mediated release of proteins from such cells could lead to a stronger immune response 
in vivo. This report illustrates that, in addition to hampering cell wall synthesis, caspo-
fungin may also interfere with the permeability of the fungal cell wall. 
Keywords antifungal, Candida, caspofungin, proteomics, proteins Introduction
The incidence of nosocomial Candida infection continues 
to rise. Candidemia has become the fourth most common 
nosocomial bloodstream infection in the USA [1] and it 
has been suggested that as many as 10,000 deaths per year 
occur in the USA due to Candida infections [2]. Candida 
albicans is the principle opportunistic yeast pathogen of 
warm-blooded animals and humans [3] and is the most 
frequently isolated Candida species from both colonized and infected sites [4]. While the polyene and azole drugs 
have long been central to antifungal therapy, the echi-
nocandins are a relatively new group of antifungal drug and 
caspofungin was the fi rst member to be licensed for use 
[5]. Unlike polyenes or azoles that bind ergosterol or dis-
rupt its biosynthesis, respectively, the echinocandins target 
the synthesis of β-1,3-glucan, the major polymer of the 
fungal cell wall [6]. Inhibition of β-1,3-glucan synthesis 
disrupts the structure of the growing cell wall, resulting in 
osmotic instability and ballooning out of the intracellular 
contents as a result of high osmotic pressure, which ulti-
mately results in cell lysis [7,8]. It has been demonstrated 
previously that upon exposure to caspofungin, C. albicans 
cells increase their chitin content [9,10]. Chitin synthesis 
is controlled in part by the PKC pathway [11] and it has 
been found that caspofungin induces a set of genes under DOI: 10.3109/13693780903405782
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the chitin synthase gene and genes involved in wall archi-
tecture. Therefore it is probable that in response to caspo-
fungin exposure yeast cells undergo a wall re-modelling 
event where the synthesis of other wall polymers, notably 
chitin, is up-regulated. In addition it has been reported that 
sub-inhibitory concentrations of caspofungin unmask glu-
can in the cell wall [13,14].
The aim of this study was to analyse the effect of caspo-
fungin on the release of peptides from C. albicans cells 
that were incubated in PBS, i.e., under conditions that did 
not support growth. One objective of this work was to 
establish whether caspofungin affects growth-arrested 
cells, since under these conditions the glucan synthase 
enzyme should not be as active as in growing cells. In 
addition it was the intention to establish the nature of pep-
tides that were released from drug-treated cells. It was 
speculated that many of the released peptides could be 
highly immunogenic in nature and thus have the potential 
to lead to tissue infl ammation in vivo. 
Materials and methods
Organism and culture conditions
Candida albicans MEN (a gift from Dr D. Kerridge, Cam-
bridge, UK) was used in this study. Cultures were grown 
in YEPD broth (2% (w/v) glucose (Sigma-Aldrich Chemi-
cal Co. Ltd, Dorset, UK), 2% (w/v) bacteriological peptone 
(Oxoid Ltd., Hampshire, England, UK) and 1% (w/v) yeast 
extract (Scharlau, Barcelona, Spain)) at 30°C and 200 rpm 
until the early stationary phase (approx. 1 x 108 cells/ml) 
was achieved. Stocks were maintained on YEPD contain-
ing 2% (w/v) agar (Scharlau), stored at 4°C and sub-
cultured every 4-6 weeks.
Assessment of amino acid release
Stationary phase cultures of C. albicans were sub-cultured 
into YEPD broth and grown to the exponential phase (4 h). 
Cells (4 × 108) were harvested (2,056 g for 5 min on a 
Beckmann GS-6 bench centrifuge) and washed twice in ster-
ile phosphate buffer (PBS; Sigma-Aldrich). Cell pellets were 
re-suspended in PBS (5 ml) with the addition of either 10% 
(v/v) dimethyl sulfoxide (DMSO; Sigma-Aldrich (used as a 
positive control)) or caspofungin (0.19 μg/ml; Merck & Co. 
Inc., NJ, USA). A negative control consisted of PBS alone. 
The suspensions were incubated at 30°C and 200 rpm for 1 
or 4 h. Cells were harvested as before and the supernatants 
collected. The release of amino acids was assessed using the 
ninhydrin colorimetric method as previously described [15]. 
A standard curve of amino acids (aspartic and glutamic acid 
(1:1) serially diluted in PBS) was prepared.© 2010 ISHAM, Medical Mycology, 48, 598–605Trypan blue assay 
Following incubation in the presence of caspofungin (0.19 
μg/ml) cells (20 μl) were removed and added to 20 μl of 
0.4% (w/v) trypan blue (Sigma-Aldrich) and 60 μl PBS. The 
mixture was allowed to rest for 5 min before examining 
under the light microscope. One hundred cells were counted 
and the number of stained and unstained cells was recorded. 
This assay was performed on three independent occasions.
Evaluation of protein release
Cultures of C. albicans were grown to the early stationary 
phase (1 × 108 cells/ml) in YEPD broth (100 ml), harvested 
and washed three times in sterile PBS. Cell pellets were 
weighed and all samples were adjusted to 1.5 g (wet 
weight). Cells were re-suspended in either PBS (5 ml), 
DMSO (10% (v/v); 5 ml) or caspofungin (0.19 μg/ml; 5 
ml) and incubated at 30°C for 4 h. A caspofungin concen-
tration of 0.19 μg/ml was chosen as this was previously 
established to be capable of inhibiting growth by 90% over 
24 h (data not shown). PBS facilitated the extraction and 
identifi cation by Matrix-assisted laser desorption/ioniza-
tion-time of fl ight-mass spectrometry (MALDI-ToF) of 
released peptides which could be masked by the presence 
of lipid, protein or other components in the growth medium 
(e.g., YEPD). Cells were harvested and the supernatants 
were placed on ice with protease inhibitors (100 μl pepsta-
tin A (1 mg/ml; Sigma-Aldrich), 100 μl aprotinin (1 mg/
ml; Sigma-Aldrich) and 100 μl phenylmethanesulfonyl 
fl uoride (PMSF; 1 mM; Sigma-Aldrich)). Samples were 
diluted 1 in 10 in 100% (v/v) trichloroacetic acid (TCA; 
dissolved in sterile distilled water; Merck) and placed at 
4°C overnight to precipitate protein. Samples were centri-
fuged at 17,950 g for 30 min at 4°C (Eppendorf centrifuge 
5417R). Protein pellets were re-suspended in ice-cold ace-
tone (300 μl; Sigma-Aldrich) and held at −20°C for at least 
1 h to further precipitate protein. Protein was centrifuged 
at 17,950 g for 30 min at 4°C (Eppendorf centrifuge 5417R) 
and the acetone was discarded. 
For one-dimensional SDS-PAGE gel analysis, released 
proteins were re-suspended in 5X sample buffer (10% 
(w/v) sodium dodecyl sulphate (SDS; Sigma-Aldrich); 5% 
(v/v) 2-mercaptoethanol (Sigma-Aldrich); 50% (v/v) glyc-
erol (Sigma-Aldrich); 0.5M Tris-HCl, pH 6.8 (Sigma-
Aldrich); 0.05% (w/v) bromophenol blue (Sigma-Aldrich)) 
and diluted 1 in 5 in this buffer before boiling. Samples 
were loaded into the wells of a 12.5% separating gel and 
run at 50 Volts for 10 min followed by 80 Volts for 120 
min (Bio-Rad, CA, USA). Protein bands were revealed 
with Coomassie blue stain (0.2% (w/v) brilliant blue R 
(Sigma-Aldich), 10% (v/v) acetic acid (Sigma-Aldrich), 
45% methanol (Sigma-Aldrich) in distilled water).
© 2010 ISHAM, Medical Mycology, 48, 598–605
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proteins were re-suspended in 250 μl IEF buffer (8 M urea 
(Sigma-Aldrich), 1% (v/v) triton X-100 (Sigma-Aldrich), 
4% (w/v) CHAPS (Sigma-Aldrich), 10 mM Tris-HCl, 2 M 
thiourea (Sigma-Aldrich), 65 mM dithiothreitol (DTT; 
added fresh; Sigma-Aldrich), 0.8% (v/v) IPG buffer pH 
3-10 (G.E. Healthcare Bio-Sciences AB, Uppsala, Swe-
den)) with a few grains of molecular-grade bromophenol 
blue. The solution was applied to a 13 cm Immobiline™ 
DryStrip pH 3-10 (G.E. Healthcare) and iso-electric focus-
ing was performed on an Ettan IPGphor II (Amersham 
Biosciences, NJ, USA). Following iso-electric focusing, 
strips were equilibrated in reducing buffer (50 mM Tris-
HCl, 6 M urea, 2% (w/v) SDS, 30% (v/v) glycerol, 2% 
(w/v) DTT, pH 6.8) for 15 min at room temperature, fol-
lowed by equilibration in alkylation buffer (50 mM Tris-
HCl, 6 M urea, 2% (w/v) SDS, 30% (v/v) glycerol, 2.5% 
(w/v) iodoacetamide (IAA; Sigma-Aldrich) and trace bro-
mophenol blue, pH 6.8) for 15 min. Strips were placed on 
top of homogeneous 12.5% SDS-PAGE gels (cast on the 
PROTEAN II casting unit (Bio-Rad); the dimensions of the 
gels were: 16 cm × 20 cm × 1 mm). Strips were overlaid 
with hand-warm sealing solution (1% (w/v) agarose 
(Sigma-Aldrich); 0.5% (w/v) bromophenol blue; 2.5 mM 
Tris-HCl, 25 mM glycine (Sigma-Aldrich), 0.01% (w/v) 
SDS). Gels were electrophoresed on the PROTEAN PLUS 
Dodeca cell system (Bio-Rad) with temperature main-
tained at 6°C using a cooling system, for 20 h at 100 Volts 
and stained with Coomassie blue stain. 
Protein was extracted from cultures on three separate 
occasions and gels were produced in triplicate per treat-
ment on each occasion.
Matrix-assisted laser desorption/ionization-time of
fl ight-mass spectrometry (MALDI-ToF MS) Analysis
Mass spectrometric analysis was performed using an Ettan 
MALDI-ToF Pro mass spectrometer (Amersham Biosci-
ences). Protein samples for peptide mass determination 
were excised from gels, washed, digested with trypsin [16] 
and deposited (1 μl) with 1 μl alpha-cyano-4-hydroxy cin-
namic acid (α-CHCA; LaserBio Labs, Sophia-Antipolis 
Cedex, France) onto mass spectrometry slides and allowed 
to dry prior to delayed extraction, refl ection ToF analysis 
at 20kV. Internal calibrants used were Angiotensin III 
(Sigma-Aldrich) and ACTH fragment 18–39 (Sigma-
Aldrich) at a fi nal concentration of 20 pM which were used 
to calibrate all spectra. The mass lists generated were 
analyzed either by (i) NCBI nr database available as part 
of the mass spectrometer Evaluation Software Version 
2.01, or (ii) Candida albicans custom database downloaded 
from The Broad Institute at: (http://www.broad.mit.edu/
annotation/genome/candida_albicans/Multihome.html).The expectation value is a measure of the statistical sig-
nifi cance of the identifi cation being true and an expectation 
value cut-off of 0.05 was imposed. The lower the expecta-
tion value the greater the certainty of the identifi cation. So 
an expectation value of zero would equate to a 100% cer-
tainty level. Mass lists were further blasted using the MAS-
COT protein search program available at http://www.
matrixscience.com. The function and information about 
these proteins was determined using the UniProt data bank 
available at http://www.uniprot.org and/or the InterPro 
website available at http://www.ebi.ac.uk/interpro/ unless 
otherwise stated. Spots were located and analyzed with 
‘Progenesis SameSpots™’ software by Nonlinear Dynam-
ics in order to quantify the fold change between treat-
ments.
Statistical analysis
All assays were preformed on three independent occasions. 
Results are expressed as the mean ± SE and were compared 
by t test using Sigma Stat Statistical analysis Package Ver-
sion 1.00 (SPSS Inc, Chicago, IL, USA). Differences were 
considered signifi cant at P  ≤ 0.05. In the case of the 1 and 
2-Dimensional gels, representative examples are presented 
in Figs. 2 and 3 respectively. 
Results and discussion
Effect of caspofungin on the leakage of amino acids
of C. albicans
The ninhydrin colorimetric method was employed to 
quantify the release of amino acids from C. albicans 
cells incubated in PBS following caspofungin treatment. 
DMSO was employed as a positive control as it has been 
shown previously to alter the permeability of the cell 
membrane and lead to the release of amino acids [17,18]. 
The results of this experiment demonstrate that after 1 
h, caspofungin leads to a small increase in amino acid 
released relative to that in the control, i.e., 20.0 μg/ml 
compared to 22.4 μg/ml in drug-treated cells (Fig. 1). 
Following 4 h exposure to caspofungin, amino acid 
release increased signifi cantly from 22.2 μg/ml in the 
control to 33.5 μg/ml in the drug-treated cells (P < 0.05). 
DMSO also caused release of amino acids after 1 and 4 h 
exposure.
As a means of assessing cell viability following caspo-
fungin exposure, a trypan blue exclusion assay was 
employed. After 1 h exposure to 0.19 μg/ml caspofungin, 
cellular viability was 95 ± 2%. This reduced to 91 ± 4% 
after 2 h and after 4 h exposure to the drug viability was 
85 ± 9%. These results demonstrate that exposure to caspo-
fungin increased the release of amino acids from the cell 
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wall and that the majority of cells remain viable after 4 h 
exposure to the drug as assessed by trypan blue exclusion. 
This result indicates that caspofungin is active against non-
growing C. albicans cells.
Effect of caspofungin on the release of proteins
from C. albicans
In order to ascertain whether caspofungin induced the 
release of proteins from C. albicans, cells were suspended 
in PBS, exposed to 0.19 μg/ml caspofungin or to 10% (v/v) 
DMSO for 4 h and the released constituents were precipi-
tated as described. Proteins were resolved on a 1-D SDS 
PAGE gel and stained with Coomassie blue (Fig. 2). It was 
evident that several small molecular weight proteins (≤ 6.5 
kDa) were released from the control cells during the 4-h 
incubation period. Cells treated with DMSO released more 
proteins, especially those of higher molecular weights (≥ 
47.5 kDa). When cells were exposed to caspofungin, 
increased release of protein was evident especially in the 
range 25–50kDa, when compared to the control. It was 
noted that the pattern of proteins released from DMSO and 
caspofungin-treated cells differs in that there was a greater 
number of larger proteins released when cells were treated 
with the DMSO.  This is possibly a result of the well estab-
lished DMSO-permeabilising effect on membranes [17] 
leading to the release of large amounts of proteins from the 
cytoplasm.
Two–dimensional SDS-PAGE was employed in order to 
further separate the released proteins and thus facilitate 
their identifi cation by mass spectrometry. Cells were 
exposed to caspofungin (0.19 μg/ml) for 4 h and the 
released proteins were collected, separated by 2-D electro-
phoresis and stained with Coomassie blue (Fig. 3).  It is 
obvious that caspofungin induced the release of a large 
number of proteins as evident by the greater number of © 2010 ISHAM, Medical Mycology, 48, 598–605protein spots (approximately 200) and an increase in spot 
intensity (Fig. 3). Selected spots were excised, washed, 
trypsin-digested and analyzed on a mass spectrometer as 
described (Table 1). The intensity of 13 peptide spots was 
increased following the treatment of cells with caspofungin 
and the intensity of these proteins was found to be increased 
by between 1.6 and 4.2 fold. Enolase 1, spot 10, is abun-
dant in the cell and is predominantly found in the cyto-
plasm, however it may also be found in the cell wall as one 
of the glucan-associated cell wall proteins [19,20]. The 
release of enolase which has been described as an allergen 
[21,22] and as an immunodominant antigen [23,24] may 
be clinically relevant as it may induce tissue infl ammation. 
Alcohol dehydrogenase, spot 12, has been found to play 
an immunogenic role during infections [25,26]. Although 
located in the cytoplasm, alcohol dehydrogenase has been 
found on the cell surface and has been implicated in adhe-
sion to host extra-cellular matrix proteins [27,28].Fig. 1 Quantifi cation of amino acid release from Candida albicans cells. 
Cells were exposed to caspofungin or DMSO for 1 or 4 h as described and 
the release of amino acids was quantifi ed using the ninhydrin assay. DMSO 
was used as a positive control at a concentration of 10% (v/v). *Indicates 
statistically signifi cant difference relative to control at P < 0.05.Fig. 2 Visualization of released proteins from Candida albicans following 
exposure to caspofungin. Cells were exposed to caspofungin or DMSO 
and released proteins were precipitated and separated by SDS-PAGE. 
Lane 1: Control, Lane 2: DMSO (10% (v/v)) treatment for 4 h, Lane 3: 
Caspofungin (0.19 μg/ml) treatment for 4 h.
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the cell wall and at the surface [29] and is believed to be 
involved in cell wall biogenesis/degradation. The intensity 
of this protein increased 2.2 fold which may implicate this 
protein in the cell’s response to caspofungin-induced cell 
wall damage.  Pyruvate kinase, spot 1, has been identifi ed 
as a wall protein [20] and was demonstrated to be highly 
immunogenic [30]. Here, caspofungin increased the release 
of this protein by 2.1 fold.
Glyceraldehyde-3-phosphate dehydrogenase, spot 8, is 
usually located in the cytoplasm but is also a surface anti-
gen [31] and was demonstrated to be capable of binding to 
the extra-cellular matrix proteins fi bronectin and laminin 
[32] thus implicating it in adherence. The intensity of this 
protein increased by 1.7 fold following caspofungin treat-
ment. The glycolytic enzyme phosphoglycerate mutase 1, 
spot 7, binds to the extra-cellular matrix protein plasmino-
gen [27] and has immunogenic properties [30,33]. 
Fructose-bisphosphate aldolase, spot 9, has also been 
implicated in plasminogen binding but with a low affi nity 
[27] and has been isolated as a cell wall protein [20] 
although it is also known to reside in the cytoplasm. Previ-
ous studies have demonstrated fructose-bisphosphate aldo-
lase to be immunogenic [30] and an IgE-binding antigen 
[21]. Importantly, when C. albicans cells are broken down 
in the human body, a large amount of glycolytic enzymes may be released and act as antigens [21]. Here it was found 
that caspofungin treatment resulted in a 1.8 fold increase 
in the intensity of fructose-bisphosphate aldolase from C. 
albicans.
The release of 6-phosphogluconate dehydrogenase, spot 
11, was found to be increased by 4.2 fold in caspofungin-
treated C. albicans cells. Six-phosphogluconate dehydro-
genase, is an oxidative carboxylase that catalyzes the 
decarboxylating reduction of 6-phosphogluconate to ribu-
lose 5-phosphate in the presence of NADP. The increased 
intensity of this protein may result from the cell wall 
remodelling known to be associated with the cell’s response 
to caspofungin [9,10] and the associated requirement of the 
cell to degrade wall associated polymers in order to facili-
tate wall re-structuring. 
Transaldolase, spot 13, is important for the balance of 
metabolites in the pentose-phosphate pathway and pro-
vides a link between the glycolytic and pentose-phosphate 
pathways and is believed to reside in the cytoplasm. Its 
intensity was increased by 2.4 fold by caspofungin. Citrate 
synthase, spot 2, which catalyzes the fi rst reaction in the 
Krebs cycle, is located in the mitochondrial matrix and 
caspofungin increased the intensity of this protein by 1.9 
fold in C. albicans. Glucan 1,3-β-glucosidase precursor, 
spot 5, catalyzes the hydrolytic removal of a glucose resi-
due at the non-reducing end of β-1,3-glucan and to a lesser Fig. 3 Visualization by 2-D electrophoresis of proteins released from Candida albicans following exposure to caspofungin. Released proteins were 
collected and separated by 2-D SDS PAGE. (A) Proteins released from cells incubated in PBS for 4 h. (B) Protein released from cells exposed to 0.19 
μg/ml caspofungin for 4 h. Numbered spots were subsequently removed and trypsin-digested prior to identifi cation by MALDI-ToF mass 
spectrometry.
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tantly, caspofungin increased the intensity of this protein 
by 1.7 fold. As this enzyme is associated with the cell wall, 
perhaps its release is due to the alteration in wall organiza-
tion in response to caspofungin.
A number of the above cell wall proteins (e.g., enolase1; 
alcohol dehydrogenase; phosphoglycerate kinase; glycer-
aldehyde-3-phosphate dehydrogenase; fructose-bisphos-
phate aldolase and 6-phosphogluconate dehydrogenase) 
were previously identifi ed as ‘atypical’ in cell wall prepa-
rations [35]. The authors postulated that some proteins 
previously believed to be cytosolic in nature may become 
entrapped within the wall of the growing cell.
The results presented here suggest that caspofungin 
induces the release of a wide range of proteins from non-
growing C. albicans cells and that these originate from 
different locations within the cell (e.g., cell wall, mitochon-
drion, cytoplasm). As caspofungin is known to interfere 
with β-1,3-glucan biosynthesis [7,8], it is not surprising to 
see the escape of many wall-associated proteins. A possible 
explanation for the release of intracellular proteins from 
caspofungin-treated C. albicans could be due to changes 
in membrane structure or composition as a result of the 
caspofungin-induced remodelling of the cell wall. It is 
interesting to note that caspofungin can induce these 
effects in non-growing cells. While viability was high after 
4 h exposure to caspofungin (85 ± 9%), the possibility 
remains that the permeability of the cell may be altered 
suffi ciently to allow the release of selected proteins. 
Interestingly, some of the proteins identifi ed here are 
known to be highly immunogenic in nature (e.g., pyruvate 
kinase, phosphoglycerate mutase, enolase 1, glyceraldehydes 
3 phosphate dehydrogenase, fructose bisphosphate aldolase 
and alcohol dehydrogenase 1). The increased release of 
these immunogenic proteins is noteworthy since from a 
clinical point of view they could lead to a stronger immune 
response and possibly infl ammation. 
The principal mode of action of caspofungin lies in its 
ability to inhibit β -1,3-glucan biosynthesis [7,8] which 
leads to osmotic instability and ultimately cell lysis. In 
addition to its direct effect on β -1,3-glucan biosynthesis, 
caspofungin also leads to the unmasking of β -1,3-glucan 
[13,14] which enhances the antifungal activity of human 
neutrophils [36] thus demonstrating that caspofungin 
makes the fungal cell more ‘visible’ to the host’s immune 
system and thus aids in its destruction. The results pre-
sented here provide further insight into the effect of caspo-
fungin on C. albicans and demonstrate that, as well as 
interfering with β -1,3-glucan synthesis, this agent induces 
the release of a range of proteins from a variety of cellular 
locations and that a number of these are known to be 
strongly immunogenic. This phenomenon may increase the 
visibility of C. albicans to the immune system and thus facilitate its destruction or alternatively challenge the host 
immune response and lead to increased infl ammation.
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